Redefining the role of interferon in the treatment of malignant diseases
- 11 November 2009
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 46 (2), 284-297
- https://doi.org/10.1016/j.ejca.2009.10.013
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- VEGF Secretion is Inhibited by Interferon-Alpha in Several Melanoma Cell LinesJournal of Interferon & Cytokine Research, 2008
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal TumorsClinical Cancer Research, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Clinical uses of interferonsBritish Journal of Clinical Pharmacology, 2007
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanomaNature Clinical Practice Oncology, 2007
- A potential predictive marker for response to interferon in malignant melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
- Estimates of the cancer incidence and mortality in Europe in 2006Annals Of Oncology, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005